Analysts Expect Ocuphire Pharma, Inc. (NASDAQ:OCUP) to Announce -$0.37 EPS

Wall Street analysts expect Ocuphire Pharma, Inc. (NASDAQ:OCUPGet Rating) to report earnings of ($0.37) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Ocuphire Pharma’s earnings. Ocuphire Pharma reported earnings of ($0.52) per share in the same quarter last year, which suggests a positive year over year growth rate of 28.8%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Ocuphire Pharma will report full-year earnings of ($1.39) per share for the current fiscal year, with EPS estimates ranging from ($1.54) to ($1.23). For the next financial year, analysts forecast that the firm will report earnings of ($1.55) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Ocuphire Pharma.

Ocuphire Pharma (NASDAQ:OCUPGet Rating) last posted its quarterly earnings results on Friday, May 13th. The company reported ($0.35) EPS for the quarter, meeting analysts’ consensus estimates of ($0.35).

A number of research analysts recently commented on the company. Zacks Investment Research raised Ocuphire Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, May 19th. HC Wainwright reissued a “buy” rating and set a $26.00 target price on shares of Ocuphire Pharma in a research note on Friday, May 20th.

In other Ocuphire Pharma news, CEO Mina Sooch bought 12,500 shares of the stock in a transaction on Thursday, May 19th. The stock was purchased at an average price of $2.07 per share, with a total value of $25,875.00. Following the completion of the purchase, the chief executive officer now owns 412,522 shares in the company, valued at $853,920.54. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 8.40% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in the company. Kestra Private Wealth Services LLC bought a new stake in shares of Ocuphire Pharma during the first quarter worth about $32,000. Bank of Montreal Can bought a new stake in shares of Ocuphire Pharma during the first quarter worth about $68,000. Powell Investment Advisors LLC bought a new stake in shares of Ocuphire Pharma during the first quarter worth about $44,000. Rice Hall James & Associates LLC grew its holdings in shares of Ocuphire Pharma by 9.5% during the first quarter. Rice Hall James & Associates LLC now owns 145,026 shares of the company’s stock worth $470,000 after purchasing an additional 12,593 shares during the last quarter. Finally, MCF Advisors LLC bought a new stake in Ocuphire Pharma in the first quarter valued at approximately $31,000. Institutional investors own 27.60% of the company’s stock.

OCUP stock traded down $0.02 during midday trading on Friday, reaching $2.09. The company had a trading volume of 101,243 shares, compared to its average volume of 192,746. The company has a market capitalization of $40.47 million, a price-to-earnings ratio of -1.42 and a beta of 0.33. The stock has a 50 day moving average price of $2.54 and a 200-day moving average price of $3.19. Ocuphire Pharma has a 1-year low of $1.80 and a 1-year high of $7.00.

Ocuphire Pharma Company Profile (Get Rating)

Ocuphire Pharma, Inc, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia.

See Also

Get a free copy of the Zacks research report on Ocuphire Pharma (OCUP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ocuphire Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocuphire Pharma and related companies with's FREE daily email newsletter.